


# The Next Wave of iBio Innovation

Amylin Receptor




# Harnessing Amylin Biology with Precision Targeting: iBio's Engineered Antibody Agonist Approach

## Why We Target Amylin

- **Validated metabolic hormone** that promotes satiety, slows gastric emptying, and reduces postprandial glucose excursions
- Clinical studies with amylin analogs confirm efficacy in weight loss, but **peptide-based approaches may be sub-optimal** (dosing, tolerability, manufacturability)<sup>1,2</sup>
- Amylin receptor-selective antibody agonists could provide a differentiated profile, with **potential for longer duration of action and reduced side effects** alone or in combination therapy

**Selective amylin receptor agonists (SARA) (rather than DACRAs\*) have potential as a more precisely targeted obesity intervention**



3. J Gingell, J. et al. An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology. *Cell Discov* 2, 16012 (2016).

\*Dual Amylin and Calcitonin Receptor Agonists



1. Aronne, L. et al. Progressive Reduction in Body Weight aft Treatment w/ Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study. *J Clin Endo Metab* 92(8)(2007)

2. Ghosh, R., Ghosh, S., & Das, A. Understanding mechanism amylin aggregation: From identifying crucial segments-tracing dominant sequential events- modeling potential aggregation suppressors. *Biochim Biophys Acta - Prot Proteomics* 1871(1) (2023)